PT Adi Sarana Armada Tbk (IDX:ASSA)

Ligand Pharmaceuticals Income Statement

Financials in millions IDR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	5,423,735	4,955,892	4,438,522	5,870,094	5,088,094	3,037,359
Revenue Growth (YoY)	22.78%	11.66%	-24.39%	15.37%	67.52%	30.12%
Cost of Revenue	3,610,993	3,340,165	3,208,739	4,700,568	3,942,447	2,162,320
Gross Profit	1,812,742	1,615,727	1,229,783	1,169,525	1,145,647	875,039
Selling, General & Admin	852,864	820,488	806,683	825,691	609,322	476,566
Other Operating Expenses	76,733	90,726	94,289	74,284	73,366	85,455
Operating Expenses	929,597	911,214	900,972	899,975	682,687	562,021
Operating Income	883,144	704,513	328,811	269,551	462,960	313,018
Interest Expense	-297,133	-294,032	-272,431	-264,307	-234,252	-249,339
Interest & Investment Income	33,546	31,160	25,307	25,237	9,356	11,876
Earnings From Equity Investments	-11,920	-12,860	-14,137	-21,498	-11,684	-3,356
Currency Exchange Gain (Loss)	446.8	-	-	-	1,192	716.86
Other Non Operating Income (Expenses)	-449.01	-	-	-	-4,641	-4,215
EBT Excluding Unusual Items	607,635	428,780	67,550	8,982	222,930	68,701
Gain (Loss) on Sale of Assets	-1,144	786.36	-2,730	-1,762	2,069	2,169
Pretax Income	606,294	429,567	64,820	7,220	224,999	70,870
Income Tax Expense	138,198	99,455	45,390	3,516	65,418	6,974
Earnings From Continuing Operations	468,095	330,111	19,430	3,704	159,581	63,896
Minority Interest in Earnings	-147,531	-86,366	84,336	99,316	-16,953	23,251
Net Income	320,564	243,745	103,767	103,020	142,628	87,148
Net Income to Common	320,564	243,745	103,767	103,020	142,628	87,148
Net Income Growth	97.13%	134.90%	0.72%	-27.77%	63.66%	-21.06%
Shares Outstanding (Basic)	3,691	3,691	3,618	3,565	3,461	3,398
Shares Outstanding (Diluted)	3,691	3,691	3,618	3,623	3,896	3,398
Shares Change (YoY)	0.28%	2.01%	-0.13%	-7.02%	14.69%	-
EPS (Basic)	86.85	66.04	28.68	28.89	41.21	25.65
EPS (Diluted)	86.85	66.04	28.68	28.44	36.60	25.65
EPS Growth	96.57%	130.27%	0.84%	-22.30%	42.69%	-21.07%
Free Cash Flow	255,495	325,220	289,679	-343,844	14,909	179,901
Free Cash Flow Per Share	69.22	88.11	80.06	-94.91	3.83	52.95
Dividend Per Share	-	-	20.000	-	-	-
Gross Margin	33.42%	32.60%	27.71%	19.92%	22.52%	28.81%
Operating Margin	16.28%	14.22%	7.41%	4.59%	9.10%	10.31%
Profit Margin	5.91%	4.92%	2.34%	1.75%	2.80%	2.87%
Free Cash Flow Margin	4.71%	6.56%	6.53%	-5.86%	0.29%	5.92%
EBITDA	1,693,207	1,503,714	1,096,762	983,535	1,069,791	868,068
EBITDA Margin	31.22%	30.34%	24.71%	16.75%	21.02%	28.58%
D&A For EBITDA	810,063	799,201	767,951	713,984	606,831	555,050
EBIT	883,144	704,513	328,811	269,551	462,960	313,018
EBIT Margin	16.28%	14.22%	7.41%	4.59%	9.10%	10.31%
Effective Tax Rate	22.79%	23.15%	70.02%	48.69%	29.07%	9.84%
Advertising Expenses	-	15,723	9,698	30,737	23,112	11,781

Updated Oct 28, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.